Migraine Therapeutic Pipeline Analysis | Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trials, and Treatment Algorithm | Satsuma Pharmaceuticals (STS101), AbbVie (atogepant)
“Migraine Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Migraine Market.
The Migraine Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
-
The report provides detailed insights about emerging therapies for the treatment of Migraine and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Migraine market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
DelveInsight’s Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Key Developments in the Migraine Therapeutics Market
• On September 20, 2022, Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) announced positive safety, tolerability, and efficacy results from its recent analysis of the ongoing ASCEND Phase 3 open-label, long-term safety trial evaluating STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine.
Learn How the Ongoing Clinical & Commercial Activities will Affect the Migraine Therapeutic Segment:
https://www.delveinsight.com/sample-request/migraine-pipeline-insight
Migraine Therapeutics Landscape
There are approx. 30+ key companies which are developing therapies for Migraine. Currently, Novartis has its Migraine drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Migraine Therapeutics Market include:
• Satsuma Pharmaceuticals
• Biohaven Pharmaceuticals
• Allodynic Therapeutics
• Vaxxinity
• AbbVie
• Pulmatrix
• AEON Biopharma
• Eli Lilly and Company
• Trevena
• Xoc Pharmaceuticals
• Pharmaleads
• Pear Therapeutics
• Axsome Therapeutics
• Impel NeuroPharma
• Zosano Pharma Corporation
And many others
Migraine Emerging Drugs Covered in the report include:
• AXS-07 (Axsome Therapeutics)
• STS-101 (Satsuma Pharmaceuticals)
• Zavegepant (Biohaven Pharmaceuticals)
• TNX1900 (Tonix Pharmaceuticals
• INP104
• M207/ADAM Zolmitriptan
And many more
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:
https://www.delveinsight.com/sample-request/migraine-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Migraine Current Treatment Patterns
4. Migraine – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Migraine Late Stage Products (Phase-III)
7. Migraine Mid-Stage Products (Phase-II)
8. Migraine Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Migraine Discontinued Products
13. Migraine Product Profiles
14. Key Companies in the Migraine Market
15. Key Products in the Migraine Therapeutics Segment
16. Dormant and Discontinued Products
17. Migraine Unmet Needs
18. Migraine Future Perspectives
19. Migraine Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/migraine-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Treatment-Resistant Depression (TRD) Market
“Treatment-Resistant Depression (TRD) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Treatment-Resistant Depression Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
, AbbVie (atogepant)){kind=link}